As the Senior Vice President of Biologics Research at Paragon Therapeutics, Inc., Michael Meehl plays a pivotal role in steering the company’s mission to discover and develop best-in-class biologics for patients facing high unmet medical needs. With over 15 years of experience in the biopharmaceutical...
As the Senior Vice President of Biologics Research at Paragon Therapeutics, Inc., Michael Meehl plays a pivotal role in steering the company’s mission to discover and develop best-in-class biologics for patients facing high unmet medical needs. With over 15 years of experience in the biopharmaceutical industry, Michael has honed his expertise in antibody discovery, protein engineering, and the developability of therapeutic candidates. His leadership is characterized by a commitment to innovative drug concepts that leverage cutting-edge protein engineering technologies.
At Paragon, Michael oversees key projects that focus on the optimization of biologics, ensuring that therapeutic proteins are not only effective but also manufacturable and scalable. His deep understanding of assay development and experimental design allows his team to create robust pipelines that translate promising drug candidates from the lab to clinical trials. Michael’s proficiency in molecular cloning and tissue culture further enhances the team's ability to engineer and produce high-quality antibodies, which are crucial for developing new therapies.
In addition to his technical skills, Michael is a strategic thinker who fosters collaboration across multidisciplinary teams to drive transformative programs forward. His dedication to improving human health through biopharmaceutical innovation positions Paragon Therapeutics as a leader in the field, committed to addressing the pressing challenges in biologics development. With a focus on the entire drug discovery process, from initial concept through to clinical application, Michael Meehl exemplifies the blend of scientific rigor and visionary leadership essential for advancing the future of therapeutic proteins.